Literature DB >> 14706589

Lymphedema after treatment of breast cancer.

Cihangir Ozaslan1, Bekir Kuru.   

Abstract

BACKGROUND: Lymphedema is one of the major long-term complications of axillary dissection. This study was designed to investigate the risk factors that are predicted to effect the development of lymphedema after complete axillary dissection.
METHODS: Two hundred forty patients who had undergone modified radical mastectomy with complete axillary dissection were examined at least 18 months after the surgery. The effects of age, diabetes, smoking, hypertension, chemotherapy, radiotherapy, tamoxifen use, stage, body mass index, number of the removed and metastatic lymph nodes, and total volume of the wound drainage on the development of lymphedema were analyzed.
RESULTS: Lymphedema developed in 68 (28%) of the 240 cases. Axillary radiotherapy and body mass index were found to increase the incidence of the lymphedema.
CONCLUSIONS: Women who had the combination of full axillary dissection and axillary radiotherapy carry a significant risk of lymphedema.

Entities:  

Mesh:

Year:  2004        PMID: 14706589     DOI: 10.1016/j.amjsurg.2002.12.003

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  54 in total

Review 1.  The new era of the lymphatic system: no longer secondary to the blood vascular system.

Authors:  Inho Choi; Sunju Lee; Young-Kwon Hong
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

2.  Metastatic breast cancer patients' expectations and priorities for symptom improvement.

Authors:  Danielle B Tometich; Catherine E Mosher; Adam T Hirsh; Kevin L Rand; Shelley A Johns; Marianne S Matthias; Samantha D Outcalt; Bryan P Schneider; Lida Mina; Anna Maria V Storniolo; Erin V Newton; Kathy D Miller
Journal:  Support Care Cancer       Date:  2018-05-07       Impact factor: 3.603

3.  Factors influencing response to lymphedema treatment in patients with breast cancer-related lymphedema.

Authors:  Sibel Eyigör; Ece Cinar; Ismail Caramat; Burcu Koc Unlu
Journal:  Support Care Cancer       Date:  2015-02-08       Impact factor: 3.603

Review 4.  Age as a risk factor for breast cancer-related lymphedema: a systematic review.

Authors:  Gunel Guliyeva; Maria T Huayllani; Daniel Boczar; Francisco R Avila; Xiaona Lu; Antonio Jorge Forte
Journal:  J Cancer Surviv       Date:  2021-01-24       Impact factor: 4.442

Review 5.  A systematic review of the effect of low-level laser therapy in the management of breast cancer-related lymphedema.

Authors:  Mohammed Taher Ahmed Omar; Afaf Ahmed Mohamed Shaheen; Hamayun Zafar
Journal:  Support Care Cancer       Date:  2012-08-09       Impact factor: 3.603

6.  The effect of prospective monitoring and early physiotherapy intervention on arm morbidity following surgery for breast cancer: a pilot study.

Authors:  Chiara Singh; Mary De Vera; Kristin L Campbell
Journal:  Physiother Can       Date:  2013       Impact factor: 1.037

Review 7.  Balancing lymphedema risk: exercise versus deconditioning for breast cancer survivors.

Authors:  Kathryn H Schmitz
Journal:  Exerc Sport Sci Rev       Date:  2010-01       Impact factor: 6.230

8.  Older breast cancer survivors: factors associated with self-reported symptoms of persistent lymphedema over 7 years of follow-up.

Authors:  Kerri M Clough-Gorr; Patricia A Ganz; Rebecca A Silliman
Journal:  Breast J       Date:  2009-11-24       Impact factor: 2.431

9.  The Health Deviation of Post-Breast Cancer Lymphedema: Symptom Assessment and Impact on Self-Care Agency.

Authors:  Jane M Armer; Mary H Henggeler; Constance W Brooks; Eris A Zagar; Sherri Homan; Bob R Stewart
Journal:  Self Care Depend Care Nurs       Date:  2008

10.  Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial.

Authors:  María Torres Lacomba; María José Yuste Sánchez; Alvaro Zapico Goñi; David Prieto Merino; Orlando Mayoral del Moral; Ester Cerezo Téllez; Elena Minayo Mogollón
Journal:  BMJ       Date:  2010-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.